Skip to main content

Clinical Trials Using Daratumumab

Review the clinical trials studying daratumumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-34 of 34

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
An Attenuated Schedule of the Dara-RVd Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 3 locations
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Venetoclax in Combination with Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody with Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Selinexor in Combination with Carfilzomib, Daratumumab or Pomalidomide, and Dexamethasone for the Treatment of Patients with Multiple Myeloma Relapsing on Current Therapy
Status: Temporarily Closed to Accrual
Location: 2 locations
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Status: Temporarily Closed to Accrual
Location: Mayo Clinic in Rochester, Rochester, Minnesota